How can Modelling and Simulation Fuel the Clinical Development of Biosimilars?
The relatively low cost to enter the “generic” market and the size of the biologic drug market make entry attractive.…
The relatively low cost to enter the “generic” market and the size of the biologic drug market make entry attractive.…
From the perspective of a clinical trial, a rare disease suggests the available patient and site population is quite small…
Bacteriophages are viruses that can be found inside plants and animals and in soil, rivers, oceans, and even sewers. Phages…
There has been considerable discussion around the concept of patientcentricity in the pharmaceutical community. The industry has taken a collective…
Where information overload has started to slow innovation and efficiency in medicinal markets, could artificial intelligence and machine learning help…
The healthcare industry needs a fully connected IT infrastructure, integrating information from multiple systems to ease administrative workloads, facilitate patient-provider…
Pharmaceutical companies have been working for years on leveraging their clinical research data in more efficient ways, but other sectors…
In this paper, Chris Hamilton, Chief Commercial Officer at CROS NT, analyses how it is important to delve into the…
In this paper, Laure Lam Hung PhD, Project Manager and Clinical Research Associate at CIDP and Dr Tarkeswarnath Bachoo MBBS,…
The US Food and Drug Administration (FDA) allows for some flexibility related to changes in clinical trial protocols—for example, with…